Oxford Biomedica is introducing digitalisation and machine learning to its systems to improve productivity and product quality.
Digitalisation of data can significantly change the healthcare industry, from how drugs are discovered and manufactured to how patients receive treatments.
Thanks to our extensive and unique experience in manufacturing lentiviral vectors, we have amassed an enormous, valuable data set. Oxford Biomedica can now digitalise its LentiVector® platform to further improve its processes. Working with the Station B team at Microsoft Research, we aim to improve the yield and quality of next generation gene therapy vectors. With Microsoft’s cloud computing, machine and deep learning capabilities, we will develop in silico models and novel algorithms to maximise production and further improve the efficiency of our LentiVector® platform